دورية أكاديمية
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
| العنوان: | Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. |
|---|---|
| المؤلفون: | Climent MA; Instituto Valenciano de Oncología (IVO), Valencia, Spain. macliment@fivo.org, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B |
| مؤلفون مشاركون: | Spanish Oncology Genitourinary Group |
| المصدر: | Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2012 Sep; Vol. 83 (3), pp. 341-52. Date of Electronic Publication: 2012 Jan 29. |
| نوع المنشور: | Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Amsterdam : Elsevier Scientific Publishers Original Publication: Boca Raton, Fla. : CRC Press, 1983- |
| مواضيع طبية MeSH: | Orchiectomy*, Prostatic Neoplasms/*pathology , Prostatic Neoplasms/*therapy, Androgen Antagonists/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Bone Neoplasms/secondary ; Bone Neoplasms/therapy ; Docetaxel ; Gonadotropin-Releasing Hormone/analogs & derivatives ; Gonadotropin-Releasing Hormone/therapeutic use ; Humans ; Male ; Neoplasm Metastasis ; Radiation-Sensitizing Agents/therapeutic use ; Taxoids/therapeutic use |
| مستخلص: | Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available. (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.) |
| المشرفين على المادة: | 0 (Androgen Antagonists) 0 (Antineoplastic Agents, Hormonal) 0 (Radiation-Sensitizing Agents) 0 (Taxoids) 15H5577CQD (Docetaxel) 33515-09-2 (Gonadotropin-Releasing Hormone) |
| تواريخ الأحداث: | Date Created: 20120131 Date Completed: 20121219 Latest Revision: 20181201 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.critrevonc.2012.01.002 |
| PMID: | 22285697 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0461 |
|---|---|
| DOI: | 10.1016/j.critrevonc.2012.01.002 |